Congress Wealth Management LLC DE Purchases 13,293 Shares of Boston Scientific Co. (NYSE:BSX)

Congress Wealth Management LLC DE increased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 6.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,387 shares of the medical equipment provider's stock after purchasing an additional 13,293 shares during the period. Congress Wealth Management LLC DE's holdings in Boston Scientific were worth $21,025,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Parnassus Investments LLC raised its stake in shares of Boston Scientific by 0.7% in the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after buying an additional 97 shares in the last quarter. PDS Planning Inc raised its position in Boston Scientific by 1.5% in the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after acquiring an additional 113 shares in the last quarter. Adero Partners LLC lifted its holdings in Boston Scientific by 3.3% in the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock valued at $334,000 after acquiring an additional 120 shares during the last quarter. Grove Bank & Trust boosted its position in shares of Boston Scientific by 4.4% during the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after purchasing an additional 122 shares in the last quarter. Finally, PFG Investments LLC grew its stake in shares of Boston Scientific by 1.6% in the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock worth $725,000 after purchasing an additional 125 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Boston Scientific news, CFO Daniel J. Brennan sold 15,087 shares of the firm's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the sale, the chief financial officer now directly owns 241,451 shares in the company, valued at $25,369,256.57. This trade represents a 5.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. This represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 137,302 shares of company stock worth $14,319,269. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Down 1.5 %

NYSE:BSX traded down $1.51 during mid-day trading on Friday, reaching $99.29. The stock had a trading volume of 7,402,670 shares, compared to its average volume of 6,051,507. The stock has a market cap of $146.86 billion, a P/E ratio of 79.43, a PEG ratio of 2.79 and a beta of 0.77. The business's 50 day moving average is $102.16 and its 200 day moving average is $93.04. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have issued reports on BSX. UBS Group lifted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Barclays upped their target price on Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Stifel Nicolaus increased their price target on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Finally, Royal Bank of Canada boosted their price objective on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.